Bremelanotide vs Melanotan II
Bremelanotide has Phase III indication-specific evidence; Melanotan II has only very small early human development and substantially weaker safety evidence.
| Attribute | Bremelanotide | Melanotan II |
|---|---|---|
| Human evidence | Two Phase III RECONNECT trials support bremelanotide for acquired generalized HSDD in premenopausal women. Older intranasal studies also reported male ED signals, but that is not the approved indication. | Very small human studies demonstrate pigmentation and erectogenic/sexual-desire effects, including placebo-controlled ED studies, but these do not establish routine therapeutic or cosmetic use. |
| Research focus | Hypoactive sexual desire disorder (HSDD) | Pigmentation and sexual-function research |
| Regulatory status | U.S. Vyleesi is approved for acquired generalized HSDD in premenopausal women; it is not indicated for men or to enhance sexual performance. | Not FDA-approved as a tanning medicine; FDA lists significant safety concerns for compounded Melanotan II. |
| Route / formulation | Research-market PT-141 is not automatically equivalent to the authorised Vyleesi product. | Small research trials do not establish safety of internet-sourced tanning products. |
Why these are compared
These compounds appear in the melanocortin / sexual-effect comparison evidence landscape, but they are not interchangeable. Bremelanotide is cyclic melanocortin receptor agonist peptide studied in hypoactive sexual desire disorder (hsdd); Melanotan II is cyclic melanocortin peptide analogue studied in pigmentation and sexual-function research. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Bremelanotide: Approved medicine — strong evidence for narrow HSDD indication.
Melanotan II: Small direct human pharmacology signals; unapproved with major safety uncertainty.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No modern head-to-head clinical trial. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.